SANTEN PHARMACEUTICAL CO.,LTD.JP:4536
| Mar 31,
2018 | Mar 31,
2019 | Mar 31,
2020 | Mar 31,
2021 | Mar 31,
2022 | Mar 31,
2023 | Mar 31,
2024 |
|---|
| Profit (loss) | 35,261 | 31,943 | 21,714 | 9,126 | 27,189 | -14,983 | 26,703 |
|---|
| Depreciation and amortization | 10,896 | 10,969 | 16,573 | 17,498 | 17,055 | 17,249 | 18,178 |
|---|
| Impairment losses (reversal of impairment losses) | 150 | - | 5,825 | 40,664 | 232 | 34,560 | 7,779 |
|---|
| Business structure improvement expenses | - | - | - | - | - | 3,225 | 5,829 |
|---|
| Share of loss (profit) of investments accounted for using equity method | - | - | - | 358 | 1,604 | 2,362 | 7,575 |
|---|
| Interest income, dividend income and interest expense | - | - | - | - | - | -469 | -303 |
|---|
| Income tax expense | 4,000 | 11,174 | 10,377 | 5,773 | 8,427 | 9,184 | 3,171 |
|---|
| Decrease (increase) in trade and other receivables | -7,116 | -6,303 | -3,054 | -7,514 | -1,965 | -6,443 | 18,384 |
|---|
| Decrease (increase) in inventories | -1,435 | -5,000 | -981 | -4,590 | 5,383 | -1,144 | -1,369 |
|---|
| Increase (decrease) in trade and other payables | 5,697 | 2,445 | 717 | 4,948 | 2,491 | 3,689 | -2,382 |
|---|
| Increase (decrease) in provisions and net defined benefit liabilities | 285 | -518 | -1,242 | -176 | -1,358 | 113 | -8,700 |
|---|
| Increase (decrease) in other current liabilities | - | - | - | - | -3,414 | 725 | 757 |
|---|
| Increase (decrease) in accounts payable - bonuses | - | - | - | - | -214 | -1,398 | 392 |
|---|
| Increase (decrease) in accounts payable - other | 961 | 1,181 | 1,305 | 3,199 | 257 | -601 | -379 |
|---|
| Increase (decrease) in deposits received | - | - | - | - | - | -591 | 7,465 |
|---|
| Other | 728 | 2,116 | 1,584 | 2,993 | 674 | -810 | 1,533 |
|---|
| Subtotal | 49,117 | 45,601 | 53,506 | 51,115 | 55,709 | 44,668 | 84,633 |
|---|
| Interest received | 145 | 187 | 200 | 195 | 323 | 300 | 467 |
|---|
| Dividends received | 598 | 521 | 581 | 490 | 497 | 461 | 486 |
|---|
| Interest paid | -27 | -8 | -190 | -159 | -240 | -465 | -830 |
|---|
| Income taxes refund (paid) | -6,990 | -13,408 | -14,149 | -12,834 | -10,246 | -7,818 | -12,108 |
|---|
| Net cash provided by (used in) operating activities | 42,843 | 32,894 | 39,947 | 38,808 | 46,043 | 37,147 | 72,649 |
|---|
| Purchase of investments | -565 | -931 | -398 | -3,384 | -1,067 | -589 | -301 |
|---|
| Proceeds from sale of investments | 2,879 | 2,156 | 3,503 | 3,070 | 3,870 | 2,149 | 4,127 |
|---|
| Purchase of investments accounted for using equity method | - | - | - | -5,349 | -2,969 | -3,470 | -207 |
|---|
| Purchase of property, plant and equipment | -3,984 | -5,470 | -5,824 | -4,139 | -17,344 | -17,277 | -9,319 |
|---|
| Purchase of intangible assets | -5,953 | -2,863 | -3,404 | -19,665 | -18,497 | -7,311 | -1,368 |
|---|
| Proceeds from sale of intangible assets | - | - | - | - | - | - | 796 |
|---|
| Other | -636 | -166 | 949 | -55 | 838 | -279 | 126 |
|---|
| Net cash provided by (used in) investing activities | -8,259 | -2,935 | -5,175 | -53,355 | -35,169 | -26,777 | -6,145 |
|---|
| Repayments of short-term borrowings | - | - | - | - | - | -11,278 | - |
|---|
| Proceeds from long-term borrowings | - | 567 | 1,477 | 307 | 10,000 | 15,639 | - |
|---|
| Repayments of long-term borrowings | -8,316 | -4,098 | -500 | -3,000 | - | -5 | -2,112 |
|---|
| Purchase of treasury shares | -1 | -14,124 | -22 | - | -12 | -26,007 | -16,962 |
|---|
| Dividends paid | -10,559 | -10,580 | -10,379 | -11,188 | -11,994 | -12,607 | -11,881 |
|---|
| Repayments of lease liabilities | - | -4 | -2,859 | -2,952 | -3,056 | -3,412 | -3,293 |
|---|
| Other | 408 | 132 | -447 | 148 | 159 | 450 | 217 |
|---|
| Net cash provided by (used in) financing activities | -17,631 | -28,107 | -12,729 | -16,685 | 5,557 | -37,220 | -34,031 |
|---|
| Net increase (decrease) in cash and cash equivalents | 16,953 | 1,852 | 22,044 | -31,232 | 16,432 | -26,850 | 32,473 |
|---|
| Effect of exchange rate changes on cash and cash equivalents | 48 | -338 | -1,410 | 2,690 | 3,694 | 1,739 | 4,206 |
|---|